Education
About Us
Working with TipRanks
Follow Us
Protara Therapeutics, Inc. (TARA)
:TARA
TARA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.60 - $10.48
Previous CloseN/A
Volume145.20K
Average Volume (3M)244.85K
Market Cap
$137.88M
Enterprise Value-$35.90M
Total Cash (Recent Filing)$68.84M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.56
Next Earnings
May 01, 2025EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding36,767,464
10 Day Avg. Volume279,619
30 Day Avg. Volume244,846
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.74
Forecast
1Y Price Target
$25.00Price Target Upside539.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Protara Therapeutics News
See All TARA News
---
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressProtara recently received FDA Fast Track designation for its investigational therapy, IV Choline Chloride.
Safety ProfileTARA-002 continues to demonstrate a favorable safety profile, with no Grade 2 or greater treatment-related adverse events and no treatment discontinuations due to adverse events.
Therapy EfficacyTARA-002 showcased promising efficacy results from the Phase II ADVANCED-2 trial in HR-NMIBC, particularly in BCG-unresponsive patients.
Bears Say
Benchmark ComparisonThe registrational cohort was ultimately powered to exclude ~20% CR at 6 months, which is acknowledged as not a functional bar given the competitive landscape.
Competitive LandscapeTARA-002 is not a first-mover nor is it clearly best-in-class with existing data.
Market CompetitionTARA-002 holds an attractive position in the treatment of NMIBC despite an increasingly competitive landscape.
---
Ownership Overview
9.56% Insiders
4.24% Mutual Funds
54.89% Other Institutional Investors
27.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TARA FAQ
What was Protara Therapeutics, Inc.’s price range in the past 12 months?
Protara Therapeutics, Inc. lowest stock price was $1.59 and its highest was $10.48 in the past 12 months.
What is Protara Therapeutics, Inc.’s market cap?
Protara Therapeutics, Inc.’s market cap is $137.88M.
When is Protara Therapeutics, Inc.’s upcoming earnings report date?
Protara Therapeutics, Inc.’s upcoming earnings report date is May 01, 2025 which is in 19 days.
How were Protara Therapeutics, Inc.’s earnings last quarter?
Protara Therapeutics, Inc. released its earnings results on Mar 05, 2025. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.565 by $0.085.
Is Protara Therapeutics, Inc. overvalued?
According to Wall Street analysts Protara Therapeutics, Inc.’s price is currently Undervalued.
Does Protara Therapeutics, Inc. pay dividends?
Protara Therapeutics, Inc. does not currently pay dividends.
What is Protara Therapeutics, Inc.’s EPS estimate?
Protara Therapeutics, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Protara Therapeutics, Inc. have?
Protara Therapeutics, Inc. has 36,767,464 shares outstanding.
What happened to Protara Therapeutics, Inc.’s price movement after its last earnings report?
Protara Therapeutics, Inc. reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.565. Following the earnings report the stock price went up 8.036%.
Which hedge fund is a major shareholder of Protara Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TARA
---
Protara Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (539.39% Upside)
$25.00 (539.39% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.53%
12-Months-Change
Fundamentals
Return on Equity
-37.88%
Trailing 12-Months
Asset Growth
129.82%
Trailing 12-Months
Company Description
Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
---
TARA Stock 12 Month Forecast
Average Price Target
$25.00
▲(539.39% Upside)
Technical Analysis
Aclaris Therapeutics
―
Innate Pharma
―
4D Molecular Therapeutics
―
TriSalus Life Sciences
―
Molecular Partners
―
Best Analysts Covering TARA
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+30.71%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +30.71% per trade.
---